Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
about
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Perspectives in the treatment of pancreatic adenocarcinomaEffectiveness and safety of s-1-based therapy compared with 5-Fluorouracil-based therapy for advanced colorectal cancer: a meta-analysisRole of targeted therapy in metastatic colorectal cancerCan we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an exampleIs conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationOral drugs in the treatment of metastatic colorectal cancer.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerGastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancyThe G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapyImpact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).Colorectal cancer in Chinese patients: current and emerging treatment options.Efficacy of S-1 in colorectal cancer.S-1 in the treatment of pancreatic cancer.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging.A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer.Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysisStanding the test of time: targeting thymidylate biosynthesis in cancer therapy.Bevacizumab: a review of its use in advanced cancer.The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
P2860
Q24658529-5D0E9233-D42C-49DF-B499-822337EA7D60Q26797248-6383F87B-7CAE-43C3-BDE4-B49BA71D0C08Q27000790-5F527ABB-A01C-4F9C-8447-9E4DAEE7717AQ28068817-AE117B7A-26DB-415F-9C54-DAB637943594Q28069620-0169FAF2-A101-405D-BEED-12F66D75903DQ28084888-3E58990F-6995-47F1-BA3B-C324E1D03F6DQ30251387-0E24F9C6-CF2B-475A-A1CD-39C4783048D5Q33416158-CEA3432E-5BAD-4999-9512-0F6E13E2ED1BQ33424566-DBD1D8A5-4DDA-4F7B-9F27-4BDCEA1F4D2CQ33427517-FB076B38-F14E-4CCC-A220-4736BCEEC810Q33435747-38100356-EEFC-4427-A729-729D1CB6DD6FQ33436476-86B909D7-4091-4C7D-A6EE-798D829AA986Q33439464-C2827650-2479-4D4A-8F54-BC7A561EA7C4Q33441606-BF2E863E-97E9-42A0-8CD6-DEC945373698Q33442681-A7C56A2B-D821-4D22-8E90-F20A92E983CDQ33624491-EB7A4868-977F-439C-9A41-1AC28BE07181Q33658466-1069C274-3EB4-4138-949D-F0FCD5B82B2BQ33739235-5D35DE75-EE30-40DB-B843-94F74295FEEBQ34000605-0FB3D268-7775-4043-8A6A-9B7C792B5F2DQ34083135-E436AA40-2097-4F78-BD9D-1B4050CE961DQ34352595-FC9A9639-0896-4DF5-B69F-905B7CF8FBFEQ34429445-9DEB792C-F308-4486-AE98-8DE7864F94DFQ34467156-A727ED67-4BF5-4E67-9EB6-58611D714DC9Q34897322-E5330A21-E494-4A83-8990-F1E37067A105Q35449912-C8D6A0E5-B236-4E2F-B3F7-B334DE063FD6Q35678690-D4A49051-596E-4731-BB3A-B1350F768323Q35756882-35B46497-1DA7-450B-9858-68AF86150A08Q35766292-E296B89A-00E6-4D3C-BE65-C3D0B0C187C6Q36324953-5488084E-AFE1-46C3-B1C2-20FFFD99FA78Q36778075-E5EF84BD-BA71-4A5D-B9D8-34C72D3BA68CQ37041204-CE87B40A-CC61-4703-8E1F-BFE850546901Q37348288-F94F3451-AF7E-4B53-B4FB-D862AE4A50E6Q37408595-7DC49730-D49A-42AE-A6DA-50A4093A00E7Q38204673-BC4B8BE3-EFA0-496E-AFEA-914E2FF228F8Q38260176-A144B99B-8807-42D5-A03D-3437A2B9C379Q38473718-EFDC6D50-894A-4BBA-9BE3-6BD7EAD95C1EQ38551668-BE0FB59C-0066-4FA0-8689-CA701030EC51Q38579560-4521F541-7526-4181-A77C-9A544308C6E9Q38619215-69A7C8BC-FDCB-4007-8FE6-5F780A84320EQ38621699-5CD9F50B-C6EA-4041-AD52-61EBD3175E44
P2860
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@en
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@nl
type
label
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@en
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@nl
prefLabel
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@en
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@nl
P2093
P921
P1433
P1476
Leucovorin, fluorouracil, and ...... ity, randomised phase 3 trial.
@en
P2093
Daisuke Takahari
Hideo Baba
Hideyuki Mishima
Hiroshi Matsumoto
Kazuhiro Yoshida
Keiichi Takahashi
Ken Shimada
Kenichi Sugihara
Masahiko Watanabe
P304
P356
10.1016/S1470-2045(13)70490-X
P577
2013-11-11T00:00:00Z